These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30692655)

  • 21. Who might benefit from early aspirin after coronary artery surgery?
    Gukop P; Gutman N; Bilkhu R; Karapanagiotidis GT
    Interact Cardiovasc Thorac Surg; 2014 Sep; 19(3):505-11. PubMed ID: 24871533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis.
    Pogosova N; Bosch J; Bhatt DL; Fox KAA; Connolly SJ; Alings M; Verhamme P; Muehlhofer E; Shestakovska O; Yusuf S; Eikelboom JW
    Circulation; 2022 Jun; 145(25):1875-1877. PubMed ID: 35728054
    [No Abstract]   [Full Text] [Related]  

  • 23. [Primary prevention of coronary heart disease with aspirin].
    Kübler W
    Z Kardiol; 2004; 93 Suppl 2():II33-6. PubMed ID: 15021994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
    Granitskiĭ NA
    Kardiologiia; 2006; 46(5):73-5. PubMed ID: 16858363
    [No Abstract]   [Full Text] [Related]  

  • 25. Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
    Tantry U; Cummings C; Mackrell P; Gonze M; Ulloa K; Bafford R; Rout A; Sukhi A; Gurbel P
    Future Cardiol; 2020 Mar; 16(2):69-75. PubMed ID: 32129681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
    Kruger PC; Guzik TJ; Eikelboom JW
    Kardiol Pol; 2019 Aug; 77(7-8):661-669. PubMed ID: 31144674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Coppens M; Weitz JI; Eikelboom JWA
    Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.
    Steinhubl SR; Topol EJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):227-31. PubMed ID: 10373712
    [No Abstract]   [Full Text] [Related]  

  • 30. Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis.
    Catanese L; Eikelboom JW; Bosch J; Shestakovska O; Ng K; Nayar S; Perera KS; Shoamanesh A; Sharma M; Hart RG
    Neurology; 2020 Aug; 95(5):e480-e487. PubMed ID: 32651298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acute subdural hematoma in a patient in treatment with apixaban and acetylsalicylic acid].
    Hernández Martín J; Vial Escolano R; Correa Ballester M
    Med Clin (Barc); 2016 Oct; 147(7):e39-40. PubMed ID: 27471015
    [No Abstract]   [Full Text] [Related]  

  • 32. Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
    McCullough PA; Marks KR
    J Thromb Thrombolysis; 1999 Jun; 7(3):233-9. PubMed ID: 10373716
    [No Abstract]   [Full Text] [Related]  

  • 33. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
    Patrono C
    Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
    [No Abstract]   [Full Text] [Related]  

  • 34. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
    Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
    Yuan J
    BMC Pharmacol Toxicol; 2018 May; 19(1):19. PubMed ID: 29720261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
    Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.
    Villablanca PA; Holmes D; Mohananey D; Briceno DF; Núñez Gil IJ; Kargoli F; Gupta T; Kizer JR; Bortnick AE; Wiley J; Menegus MA; Pyo R; García M; Ramakrishna H; Mookadam F
    Coron Artery Dis; 2017 Aug; 28(5):395-405. PubMed ID: 28328784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed.
    Tsilimigras DI; Sigala F; Kontogiannis C; Moris D
    J Am Coll Cardiol; 2019 May; 73(18):2359-2360. PubMed ID: 31072583
    [No Abstract]   [Full Text] [Related]  

  • 39. The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
    Eikelboom R; Muller Moran HR; Lodewyks C; Yan W; Zelentsov I; Arora RC
    Curr Opin Cardiol; 2020 Sep; 35(5):583-588. PubMed ID: 32649352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response by Fox to Letter Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease".
    Fox KAA
    Circulation; 2021 Jan; 143(1):e3. PubMed ID: 33378237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.